Aspira Women's Health Inc

Aspira Women's Health Inc AWH

Dividend Summary

There have not been any declared dividends recently.

Latest Dividends
Summary Previous dividend Next dividend
Per share
Declaration date
Ex-div date
Pay date

Enter the number of Aspira Women's Health Inc shares you hold and we'll calculate your dividend payments:

Previous Payment
Next Payment
Forecast Accuracy
We have not made any dividend predictions for Aspira Women's Health Inc
Dividend Yield Today
The dividend yield is calculated by dividing the annual dividend payment by the prevailing share price
The table below shows the full dividend history for Aspira Women's Health Inc
Status Type Decl. date Ex-div date Pay date Decl. Currency Forecast amount Decl. amount Accuracy
There are no Aspira Women's Health Inc dividends.
Year Amount Change
2006 0.0c
2007 0.0c
2008 0.0c
2009 0.0c
2010 0.0c
2011 0.0c
2012 0.0c
2013 0.0c
2014 0.0c
2015 0.0c
2016 0.0c
2017 0.0c
2018 0.0c
2019 0.0c
2020 0.0c
2021 0.0c
2022 0.0c
2023 0.0c
2024 Sign Up Required

Aspira Women's Health Inc Optimized Dividend Chart

The chart below shows the optimized dividends for this security over a rolling 12-month period.
Dividend Yield Today
Optimized Yield
Sign Up Required
52 Week High
0.0% on 11 August 2023
52 Week Low
0.0% on 11 August 2023
Next Ex-Div-Date Countdown
Sign Up Required

About Aspira Women's Health Inc

Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering. Its product pipeline includes OvaWatch, a non-invasive blood-based risk assessment test to determine ovarian cancer risk for patients with an adnexal mass; and Endocheck, an in-development non-invasive blood test designed as an aid in the identification of endometriosis for patients with suspected endometriosis earlier in their prognosis journey. In addition, the company operates Aspira Synergy, a testing platform and cloud service; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force, its platform Aspira Synergy, and a marketing and distribution agreement with BioReference Health, LLC. It has a research agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.

Pharmaceuticals & Biotechnology
United States
Share Price
$2.66 (yesterday's closing price)
Shares in Issue
12 million
Market Cap
The Consecutive Annual Dividend Increases - the number of years this company has been increasing its dividends
Market Indices
No articles found